Advanced cSCC: What to Do When Surgery Just Isn’t Going to Cut It

Activity Overview

While attending EADO 2020, please join our faculty as they address pressing questions about unresectable cutaneous squamous cell carcinoma (CSCC). Using real-world patient cases, they will demonstrate how and when to safely incorporate new and emerging immune checkpoint inhibitors into your practice for patients in whom surgery may not be an option.
Location: Radisson Blu Hotel, Hall Alfa | Vilnius, Lithuania

LIVE ACTIVITY

Target Audience

Oncology, dermatology, and dermato-oncology clinicians who manage patients with cutaneous squamous cell carcinoma (CSCC).

Learning Objectives

Upon successful completion of this education activity, participants should be better able to:

  • Effectively identify cutaneous squamous cell carcinoma (CSCC) and assess risk of developing advanced disease
  • Delineate the safety and efficacy of immunotherapeutic agents for CSCC
  • Effectively manage immune-mediated adverse reactions associated with the mechanism of action of checkpoint inhibitors
  • Select therapy for individual patients according to current evidence and guidelines, offering clinical trial enrollment where appropriate

 

Activity Faculty

ModiB

Badri Modi, MD (Chair)

Assistant Clinical Professor, Division of Dermatology
Department of Surgery
City of Hope
Duarte, CA, USA

BranaI

Irene Braña, MD, PhD

Clinical Investigator, Molecular Therapeutic Research Unit and ENT Unit
Vall d’Hebron University Hospital
Vall d’Hebron Institute of Oncology (VHIO)
Barcelona, Spain

MorenoV

Victor Moreno, MD, PhD

Director, Early Phase Clinical Trials Unit
START Madrid-FJD, Hospital Fundación Jiménez Díaz
Madrid, Spain